PD-1 | ApexOnco - Clinical Trials news and analysis

“Top quality, fast and so easy to use”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

Data insights

29 November 2024

The month ahead: December’s upcoming events

Party season approaches; but first, conferences.

Regulatory

27 November 2024

EU backs Tevimbra's stomach restriction – and then some

Data insights

27 November 2024

Merck gets high with subcutaneous Keytruda

Trial results

19 November 2024

Merck finally gets under the skin with Keytruda

Deals

14 November 2024

Merck & Co gets in on the bispecific act

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

Deals

29 October 2024

GlycoMimetics gets on the PD-1/VEGF bandwagon

Regulatory

28 October 2024

Another PD-1/VEGF bispecific emerges

Deals

18 October 2024

LaNova enters oncology’s hottest licensing territory

Data insights

14 October 2024

Genmab presses on with acasunlimab

Conferences Data insights

10 October 2024

No stopping Astra’s pivotal TIGIT plan

Subscribe to PD-1

The month ahead: December’s upcoming events

EU backs Tevimbra's stomach restriction – and then some

Merck gets high with subcutaneous Keytruda

Merck finally gets under the skin with Keytruda

Merck & Co gets in on the bispecific act

GlycoMimetics gets on the PD-1/VEGF bandwagon

Another PD-1/VEGF bispecific emerges

LaNova enters oncology’s hottest licensing territory

Genmab presses on with acasunlimab

No stopping Astra’s pivotal TIGIT plan

Recent Quick take

Most Popular